Short Interest in Aptorum Group Limited (NASDAQ:APM) Rises By 195.3%

Aptorum Group Limited (NASDAQ:APM) was the recipient of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 3,027 shares, an increase of 195.3% from the January 15th total of 1,025 shares. Based on an average trading volume of 53,704 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the company’s shares are sold short. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 53,704 shares, the days-to-cover ratio is currently 0.1 days.

Aptorum Group Stock Up 2.7%

Shares of APM stock opened at $0.85 on Friday. Aptorum Group has a 52 week low of $0.69 and a 52 week high of $4.47. The firm has a 50 day moving average of $1.05 and a 200-day moving average of $1.46.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Aptorum Group presently has an average rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.